Infectious disease therapeutics includes products used for the treatment of various bacterial, viral and fungal infections. Some key products are antibiotics, antivirals and antifungals. These products are used for both human and animal care. The rising burden of infectious diseases worldwide is driving significant demand for new and effective therapeutic solutions.

The infectious disease therapeutics market is estimated to be valued at US$ 170.67 Bn in 2023 and is expected to exhibit a CAGR of 3.7% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The market is expected to witness strong growth over the forecast period owing to rising prevalence of infectious diseases worldwide coupled with growing antibiotic resistance. According to the World Health Organization (WHO), infectious diseases accounted for approximately 26% of global deaths in 2020. Growing investment by pharmaceutical companies in development of novel drugs and therapies for drug resistant bacteria is also likely to support market growth. Furthermore, growth in pet care spending and rising incidence of zoonotic diseases is boosting demand for veterinary infectious disease therapeutics.

SWOT Analysis
Strength: The infectious disease therapeutics market possesses strong pipeline products, which are expected to receive marketing approval and get launched in the coming years. In addition, majority of innovative drugs in the pipeline are targeted towards infection diseases with high unmet need. Further, ongoing research and development activities by market players is leading to development of novel drug classes and mechanism of actions to treat infectious diseases.
Weakness: High costs associated with research and development of novel drugs for infectious disease indication. Further, market fragmentation owing to presence of generic competition once patents of blockbuster drugs expire limits growth potential of innovative drugs.
Opportunity: Increasing prevalence of drug-resistant microbial strains globally due to suboptimal treatment practices presents immense scope for development and commercialization of novel anti-infectives. Further, rising healthcare expenditure in developing countries boosts potential market size expansion opportunities over the forecast period.
Threats: Stringent regulatory processes for approval of new anti-infective drugs increases risk of clinical trial failure and delays market entry. Additionally, expiry of patents of major drugs results in decline of their revenues posing significant threat.

Key Takeaways
The global Infectious Disease Therapeutics market is expected to witness high growth, exhibiting CAGR of 3.7% over the forecast period, due to increasing prevalence of drug-resistant microbial infections worldwide.

North America is expected to dominate the global market owing to presence of majority of innovator companies and continuous product pipeline enrichments. Europe is anticipated to hold the second largest market share due to rising research and development activities for treatment of infectious diseases.

Asia Pacific is estimated to exhibit the fastest growth during the forecast period, owing to rising healthcare expenditure, growing awareness regarding availability of effective treatment options, and increasing presence of market players in the region.

Key players: Key players operating in the infectious disease therapeutics market are Novartis International AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, F. Hoffmann-La Roche AG, BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH. among others.